Charles River Laboratories
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry (for example, contract research organization services) and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
| Company type | Public |
|---|---|
Traded as |
|
| Industry |
|
| Founded | 1947 |
| Headquarters | Wilmington, Massachusetts, U.S. |
Key people | James C. Foster (CEO) |
| Revenue | US$4.13 billion (2023) |
| US$617 million (2023) | |
Net income | US$474 million (2023) |
| Total assets | US$8.19 billion (2023) |
| Total equity | US$3.60 billion (2023) |
Number of employees | c. 21,800 (2023) |
| Website | criver |
| Footnotes / references | |
According to the company, it supported the development of approximately 85% of novel FDA-approved drugs in 2021.
Its customers include leading pharmaceutical, biotechnology, agrochemical, government, and academic organization around the globe. The company has over 90 facilities, operates in 20 countries, and employs approximately 18,400 people worldwide.
Charles River Laboratories is often criticized by animal rights activists who condemn the company's usage of dogs and non-human primates for pharmaceutical purposes. The company is also a major harvester of horseshoe crab blood.